SRPT
Sarepta Therapeutics Inc
20.10$
+0.1%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 84.0% | 82.0% | 88.1% | 93.9% | 86.9% | 80.6% | 83.3% | 82.7% | 81.8% | 79.0% | 77.6% | 75.8% | |
| 24.9% | 29.3% | 28.9% | 45.8% | 22.6% | 45.8% | 50.3% | 67.2% | 30.9% | 13.1% | 27.8% | 23.9% | |
| 71.3% | 70.3% | 74.9% | 82.5% | 71.5% | 61.7% | 64.9% | 67.2% | 63.6% | 51.3% | 34.2% | 28.1% | |
| 0.8% | 1.5% | 1.2% | 2.3% | 3.0% | 5.2% | 4.6% | 5.5% | 8.4% | 13.4% | 16.4% | 15.5% | |
| 11.3% | 9.8% | 3.0% | 6.4% | 7.6% | 9.4% | 7.8% | 5.9% | 6.5% | 9.9% | 18.9% | 27.3% | |
| 13.0% | 13.6% | 8.9% | 3.3% | 5.9% | 7.1% | 6.4% | 6.1% | 7.8% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 2.0% | 2.4% | 1.9% | 1.1% | 0.7% | 0.7% | 0.5% | 0.5% | 0.2% | 0.9% | 0.7% | 0.9% | |
| 16.1% | 30.5% | 20.6% | 39.7% | 37.1% | 55.1% | 74.5% | 70.5% | 87.7% | 73.7% | 61.5% | 65.9% | |
| 12.5% | 22.8% | 17.8% | 6.8% | 10.6% | 14.5% | 13.9% | 14.4% | 19.8% | 20.0% | 18.5% | 32.7% | |
| 0.9% | 3.1% | 2.4% | 0.5% | 8.2% | 0.4% | 6.5% | 8.6% | 0.5% | 3.8% | 0.3% | 0.3% | |
| 4.2% | 7.4% | 7.0% | 0.6% | 2.1% | 3.7% | 3.7% | 2.4% | 3.1% | 5.1% | 5.4% | 8.4% | |
| 1.3% | 5.5% | 1.4% | 32.5% | 25.6% | 37.4% | 33.3% | 34.8% | 49.4% | 34.7% | 28.7% | 24.7% | |
| 83.9% | 69.5% | 79.4% | 60.3% | 62.9% | 44.9% | 25.5% | 29.5% | 12.3% | 26.3% | 38.5% | 34.1% | |
| -230.2% | -328.4% | -275.0% | -93.0% | -96.2% | -125.8% | -95.4% | -101.9% | -125.0% | -136.2% | -106.3% | -145.6% | |
| 13.6% | 15.4% | 11.5% | 4.5% | 4.0% | 4.0% | 2.6% | 2.6% | 2.8% | 2.8% | 2.7% | 3.1% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.